Hemarina
Hemarina is a French biotech developing therapeutic oxygen carriers derived from marine lugworm (Arenicola marina) hemoglobin. Its lead product HEMO2life® is a CE-marked medical device for organ preservation, serving hospitals, transplant centers, and military medical institutions across Europe, the US, and India.
- Company typePrivate
- Founded2007
- HeadquartersMorlaix, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hemarina does
Hemarina is a privately-held French biotechnology company founded in 2007 as a spin-off from CNRS and Sorbonne University, headquartered in Morlaix, Brittany. The company develops a portfolio of therapeutic and industrial products based on a single proprietary technology platform, M101, which leverages the extracellular hemoglobin extracted from the marine lugworm Arenicola marina. Hemarina controls its raw material supply end-to-end through the 13-hectare Ferme Marine de Noirmoutier aquaculture facility in France, producing approximately 30 tonnes of marine worms annually, and outsources industrial-scale manufacturing to Delpharm at their Tours, France plant.
The company's lead commercial product, HEMO2life®, is a CE-marked medical device additive to organ preservation solutions. It is described as universal across blood types, stable at ambient temperature for over two years, and capable of binding 40 times more oxygen than human hemoglobin, supporting applications in kidney, face, and limb transplantation. The broader product portfolio includes HEMOXYCarrier® (universal oxygen therapeutic), HEMHealing® (oxygenating wound dressing), HEMDental-Care® (periodontal treatment), HEMOXCell® and HEMBoost® (industrial bioproduction inputs), and HEMDental-Regenerativ® (dental bone regeneration).
Hemarina operates an enterprise field sales motion targeting hospital transplant centers, academic medical centers, and military medical institutions in France, Europe, the United States (via a Boston office and US Navy collaboration), and India (via the Amrita Institute of Medical Sciences partnership). The OxyOp2 multicentric trial with 460 patients across all French transplant centers is the company's pivotal clinical program. Notable milestones include the 2019 CE marking, the 2021 world's first bilateral upper limb transplant at AIMS in India, the 2022 face transplant of a French soldier with presidential validation, the 2023 Prix Galien France award in the medical device category, and the 2026 European Inventor Award finalist recognition for founder Dr. Franck Zal. Revenue figures are not publicly disclosed, and no US FDA approval has been announced.
Hemarina firmographics
Firmographics- Name
- Hemarina
- Legal name
- Hemarina SA
- Website
- https://hemarina.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Hemarina is a French biotech developing therapeutic oxygen carriers derived from marine lugworm (Arenicola marina) hemoglobin. Its lead product HEMO2life® is a CE-marked medical device for organ preservation, serving hospitals, transplant centers, and military medical institutions across Europe, the US, and India.
- Ownership category
- akta.pro rank
Hemarina industry classification
Industry- Product category
- Medical Biotechnology - Oxygen Carrier Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)
- akta.pro secondary industry
- Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL)
Keywords
Where Hemarina is headquartered
LocationHeadquarters
- HQ city
- Morlaix
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Hemarina business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- HEMO2life® Medical Device Sales: Revenue generated from the sale of HEMO2life®, a medical device used for organ preservation and as an oxygen therapeutic. Sales are made directly to hospitals and medical institutions, primarily for transplant procedures, emergency medicine, and military medical applications. Revenue is recognized upon delivery to healthcare institutions following regulatory approvals and hospital procurement processes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B institutional pricing for healthcare providers |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Hemarina product offering
Product offeringCore offering
Hemarina develops, manufactures, and sells medical devices and therapeutic products based on its proprietary M101 platform, leveraging extracellular hemoglobin extracted from the marine lugworm Arenicola marina. Its flagship HEMO2life® is a CE-marked organ preservation additive used in kidney, face, and limb transplants, while the broader portfolio addresses oxygen therapy, wound healing, dental care, and industrial bioproduction. The company sells these prescription products and bioprocessing inputs directly to hospitals, transplant centers, military medical institutions, and industrial customers.
Product overview
Hemarina is a biotechnology company with a proprietary technology platform (M101) based on extracellular hemoglobin extracted from the marine lugworm Arenicola marina. The company's product portfolio includes six therapeutic and industrial products: HEMO2life® (organ preservation additive), HEMOXYCarrier® (universal oxygen carrier), HEMHealing® (wound healing hydrogel), HEMDental-Care® (periodontal treatment gel), HEMOXCell® (cell growth activator), and HEMBoost® (bioproduction input). The M101 molecule is unique in that it is extracellular (not contained in red blood cells), universal (compatible with all blood types), binds 40 times more oxygen than human hemoglobin, and is 250 times smaller than human red blood cells. The products address ischemic diseases where oxygen delivery is compromised, including organ transplantation, wound healing, and dental applications.
Differentiator
Problem solved
Functional benefit
Brands
- HEMO2life®: Additive to organ preservation solutions - universal oxygen carrier medical device derived from Arenicola marina lugworm hemoglobin for graft preservation
- HEMOXYCarrier®
- HEMHealing®
- HEMDental-Care®
- HEMDental-Regenerativ®
- HEMOXCell®
- HEMBoost®
Products and services
- HEMO2life® CE-marked medical device additive to organ preservation solutions, derived from extracellular hemoglobin of the marine lugworm Arenicola marina. Binds 40 times more oxygen than human hemoglobin and reduces ischemia-reperfusion injury during graft preservation. Used by hospital transplant centers in kidney, face, and limb transplant procedures.
- HEMOXYCarrier® Universal therapeutic oxygen carrier based on the M101 hemoglobin platform for medical applications requiring direct oxygen delivery to tissues and organs. Designed for emergency transfusion, acute anemia treatment, and oxygenation support in hospital and military medicine settings.
- HEMHealing® Oxygenating hydrogel wound dressing that releases physiological oxygen to damaged tissues to enhance regeneration and reduce healing time, with primary applications in burns and chronic wounds. Awarded the Prix Galien de l'Année 2023 in the medical device category.
- HEMDental-Care® Oxygenating hydrogel for dental applications, designed for periodontal treatment with demonstrated anti-inflammatory and anti-bacterial properties for the management of periodontitis.
- HEMOXCell® Cell growth activator for industrial bioproduction applications. Leverages the oxygen-carrying properties of the M101 molecule to enhance cell viability and productivity in bioreactor systems for pharmaceutical and biotech manufacturing customers.
- HEMBoost® Input for industrial bioproduction designed to enhance productivity in biomanufacturing processes through improved oxygenation of cell cultures.
Quantifiable outcome
- 40 times greater oxygen-carrying capacity compared to human hemoglobin
- +3 more outcomes
Companies that use Hemarina
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Hemarina technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Hemarina partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, flagship and major.
- DelpharmcoreManufacturing partnership with Delpharm, a leading pharmaceutical contract manufacturer, for the industrial-scale production of HEMO2life® medical device. This partnership enables Hemarina to scale manufacturing capacity beyond its pilot facilities while leveraging Delpharm's expertise in aseptic manufacturing and regulatory compliance for pharmaceutical products.
- Amrita Institute of Medical Sciences (AIMS)flagshipClinical partnership with Amrita Institute of Medical Sciences in Kochi, India for the use of HEMO2life® in transplant procedures. AIMS performed the world's first bilateral upper limb transplant using HEMO2life® in 2016, establishing a landmark clinical reference case.
- Brest University Hospital (CHRU de Brest)coreClinical trial partnership for the OxyOp2 study evaluating HEMO2life® in organ preservation applications. The hospital serves as a key clinical research site generating pivotal evidence for regulatory approvals and clinical adoption.
- Naval Medical Research Center / US NavymajorPreclinical collaboration with the US Navy's Naval Medical Research Center for military medical applications of HEMO2life®, including battlefield hemorrhage control, emergency field transfusion, and combat casualty care.
Scale indicators4 records
Recent moves8 records
Expansion highlights7 records
Hemarina competitors and assessment
Company assessmentDirect peers
- NuvOx Pharma: Develops dodecafluoropentane-based oxygen therapeutics for cancer, stroke, and other ischemic conditions. Competes in the same oxygen-carrier therapeutic space with alternative chemistry approach but overlapping indications.
- Cellphire Therapeutics: Develops Thrombosomes (lyophilized platelets) and other blood-product substitutes for hemorrhage and trauma. Operates in the same blood-substitute therapeutic space with comparable emergency medicine and military positioning.
- Bridge to Life: Supplier of organ preservation solutions including Belzer UW and static cold storage products used as the baseline medium in transplant workflows. Competes directly with HEMO2life® as a preservation additive and could be a commercial channel partner.
- Prolong Pharmaceuticals: Developed Sanguinate, a PEGylated bovine hemoglobin-based oxygen carrier for sickle cell disease and other ischemic conditions. Directly comparable hemoglobin-based therapeutic platform pursuing similar hematology and oxygen-delivery indications.
- HbO2 Therapeutics: Develops Hemopure (hemoglobin-based oxygen carrier from bovine source) for surgery and trauma indications. Closest direct competitor in the HBOC therapeutic class with overlapping universal-donor positioning and surgical use cases.
Broad incumbents
- XVIVO Perfusion: Swedish-listed organ preservation company with leading lung perfusion technology (Steen solution) and expanding into abdominal organ preservation. Established commercial player in the same transplant workflow where HEMO2life® is positioned as an additive.
- Grifols: Global plasma-derived therapies leader producing hemoglobin-based and plasma-based blood products. Represents the established incumbent in hematology and blood-related biologics that Hemarina's marine hemoglobin platform could eventually compete with or complement.
- OrganOx: Develops normothermic machine perfusion technology for liver and kidney preservation. Represents the leading alternative platform to HEMO2life® in the organ preservation workflow, particularly in European transplant centers.
- TransMedics Group: Market leader in normothermic organ preservation systems for lung, heart, and liver transplants. Competes indirectly with HEMO2life® by offering an alternative preservation paradigm that may absorb or substitute for hemoglobin-based additives.
Emerging players
- Aurum Biosciences: Develops oxygen-loaded nanobubble therapeutics for stroke and oncology. Competes in the oxygen-delivery therapeutic space with a different delivery mechanism (nanobubbles vs. extracellular hemoglobin) but overlapping clinical applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Hemarina social profiles
Digital presenceHemarina financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hemarina leadership team
Management profileNumber of profiles
Profiles6 records
Hemarina funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hemarina M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hemarina
What does Hemarina do?
Hemarina develops, manufactures, and sells medical devices and therapeutic products based on its proprietary M101 platform, leveraging extracellular hemoglobin extracted from the marine lugworm Arenicola marina. Its flagship HEMO2life® is a CE-marked organ preservation additive used in kidney, face, and limb transplants, while the broader portfolio addresses oxygen therapy, wound healing, dental care, and industrial bioproduction. The company sells these prescription products and bioprocessing inputs directly to hospitals, transplant centers, military medical institutions, and industrial customers.
Is Hemarina a public or private company?
Hemarina is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hemarina founded?
Hemarina was founded in 2007. It employs 11 to 50 people.
Where is Hemarina based?
Hemarina is headquartered in Morlaix, France, in the Europe region.
How does Hemarina make money?
One revenue line is on record: HEMO2life® Medical Device Sales.
Who are Hemarina's main competitors?
Direct peers on record are NuvOx Pharma, Cellphire Therapeutics, Bridge to Life, Prolong Pharmaceuticals and HbO2 Therapeutics. Broad incumbents are XVIVO Perfusion, Grifols, OrganOx and TransMedics Group. Aurum Biosciences is listed as an emerging player.
Does Hemarina have an API?
No public API is recorded for Hemarina.
What industry is Hemarina in?
Hemarina's product category is Medical Biotechnology - Oxygen Carrier Therapeutics. Its primary akta.pro industry code is HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant), with a secondary code of HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics). Its NAICS code is 325414 and its SIC code is 2836.